Company
Headquarters: Oxford, United Kingdom
Employees: 92
| Company | Market Cap (USD) |
|---|---|
| Abbott | $213.72 B |
| Stryker | $150.01 B |
| Boston Scientific Corporation | $149.80 B |
| Medtronic | $114.44 B |
| Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $47.37 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
NIOX Group Plc, engages in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNo), a biomarker for asthma worldwide. Its products include NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device and a range of consumables, including sensors, individual disposable mouthpieces, and breathing handles for the measurement of FeNo level in patients. The company was formerly known as Circassia Group Plc and changed its name to NIOX Group Plc in September 2022. NIOX Group Plc was incorporated in 2006 and is headquartered in Oxford, the United Kingdom.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | £36.8 M |
| EBITDA | £8.6 M |
| Gross Profit TTM | £26.5 M |
| Profit Margin | 29.08% |
| Operating Margin | 8.89% |
| Quarterly Revenue Growth | 13.90% |
NIOX Group Plc has the following listings and related stock indices.
Stock: LSE: NIOX wb_incandescent